Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc DSGN with a Sell rating and a $10 price target. 

  • The analyst Madhu Kumar has caution about the Company's lead indication of Friedreich ataxia. 
  • Natural history studies provide little support that differences in FXN levels will shift the FA disease course. 
  • At the same time, high-dose nicotinamide has already achieved clinically meaningful FXN induction with the minimal observed change in clinical effect in FA patients, Kumar tells investors in a research note. 
  • He believes Design shares are "priced with little room for error."
  • In September, the Company posted new preclinical data from its novel DM1 GeneTAC program.
  • The data demonstrated DM1 GeneTAC's potential to potently and selectively block the mutant DMPK gene expression in DM1 patient cells. 
  • Reduction of nuclear foci was associated with clear correction of splicing defects involved in the multi-system pathophysiology of DM1.
  • Price Action: DSGN shares are down 4.85% at $14.13 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!